Award
NIH Reporter #1R01AR088178-01
Mechanisms of response to CD19 redirected PluriReceptor NK cells in systemic autoimmunity
Recipient
University of Texas Health Science Center Houston
Award Amount
$421,040.00
Ceiling
$421,040.00
Awarded
August 28, 2026
Identifier
1R01AR088178-01
NIH NIAMS awarded $421,040 for a clinical trial studying AD-PluReceptor-NK cells with Tafasitamab in systemic autoimmunity, focusing on molecular profiling and immune mechanisms.
Description
This project involves a clinical trial assessing the safety and efficacy of AD-PluReceptor-NK cells combined with Tafasitamab for systemic autoimmunity conditions such as systemic sclerosis and systemic lupus erythematosus. The funding is provided by the NIH NIAMS, with a total award amount of $421,040 for the fiscal year 2026. The project emphasizes molecular profiling and immune mechanism elucidation.